Success Story: AEGERION PHARMACEUTICALS K.K., a pharmaceutical company that specializes in the development and commercialization of innovative therapies for rare diseases, released an oral drug for homozygous familial hypercholesterolemia (HoFH)

May 17, 2017

AEGERION PHARMACEUTICALS K.K.—a Japanese subsidiary of Aegerion Pharmaceuticals Inc., a U.S. pharmaceutical company that specializes in the development and commercialization of innovative therapies for rare diseases—released an oral drug in December 2016 that features a new mechanism of action for homozygous familial hypercholesterolemia (HoFH). This drug raises hopes of alleviating the burden on Japanese patients suffering from this rare disease.

For more information about other cases, please see the Success Stories.